The same study, confirmed by others, proved a synergy between ibrutinib and inhibition of IRAK4, a mediator for TLR and NFκB activation whose targeting is studied not only in DLBCL but in CLL as well (129, 175, 176). This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.